CRO / CMO / CDMO

Delve into the world of CRO / CMO / CDMO in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on CRO / CMO / CDMO to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program
CompanyDeals

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Ltd. ("Porton Advanced Solutions") and Hangzhou Aisijia Biotech Co., Ltd. ("Aisijia Biotech") announced a strategic collaboration centered on the new drug clinical trial (IND) application in China…

EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
CompanyDeals

Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million

CompanyDeals

Signet Therapeutics and Jennio Biotech Join Forces to Advance Tumor Immunotherapy

Company

Celltrion Inc. Enters CDMO Arena Amid Shifts in Global Biosecurity Landscape

CompanyDeals

Itcure Expands Gene Editing Reach with Collaborations in China’s Biotech Sector

CompanyDeals

Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation

CompanyDeals

Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024

CompanyDeals

WuXi Biologics to Acquire Full Control of Vaccine Contract Services Subsidiary for $108.5 Million

Company

WuXi Biologics Reports Flat Revenues with Growth in Non-COVID-19 Projects in 2024H1 Financial Report

Show More